Weibo Cai, PHD

Pubmed

More information:

• Cai Laboratory Home Page

Dr. Cai is a Vilas Distinguished Achievement Professor

He is also a Fellow of the American Institute for Medical and Biological Engineering (AIMBE, 2018), Fellow of the Society of Nuclear Medicine and Molecular Imaging (SNMMI, 2019), and Fellow of the Royal Society of Chemistry (RSC, 2021).

Research Description:

Research of the Cai Group is focused on three areas: 1) development of multimodality molecular imaging agents; 2) nanotechnology and its biomedical applications; and 3) molecular therapy of cancer.

Personalized medicine is the future of 21st century patient management and molecular imaging can play pivotal roles in disease diagnosis, treatment efficacy assessment, and drug development. In addition, molecular imaging is an extremely powerful tool in multiple disciplines of biomedical research including regenerative medicine. The imaging techniques routinely used in our research include positron emission tomography (PET), bioluminescence, fluorescence, and magnetic resonance imaging (MRI).

Selected References:

• Hong H, Yang Y, Zhang Y, Cai W. Non-invasive imaging of human embryonic stem cells. Current Pharmaceutical Biotechnology, 2010, 11, 685-692.
• Cai W,  Zhang Y, Kamp TJ. Imaging of induced pluripotent stem cells: from cellular reprogramming to transplantation. Am J Nucl Med Mol Imaging 2011;1(1):18-28.
• Lewis CM, Graves SA, Hernandez R, Valdovinos HF, Barnhart TE, Cai W, Meyerand ME, Nickles RJ, Suzuki M.⁵²Mn production for PET/MRI tracking of human stem cells expressing divalent metal transporter 1 (DMT1). Theranostics. 2015, 5(3), 227-239.
• England CG, Ehlerding EB, Cai W. Imaging the Biodistribution and Performance of Transplanted Stem Cells with PET. J Nucl Med. 2016, 57(9):1331-1332.
• Wei W, Ehlerding EB, Lan X, Luo Q, Cai W. Molecular imaging of β-cells: Diabetes and beyond. Advanced Drug Delivery Reviews, 2018, ePub. Adv Drug Deliv Rev, 2019, 139:16-31.